2024-11-06 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis:

**1. Performance Comparison:**

Abbott Laboratories (ABT) is a healthcare company that develops, manufactures, and sells pharmaceuticals, medical devices, nutritional products, and diagnostics.  

The cumulative return of ABT is **110.28%**, while the S&P 500 (VOO) has a cumulative return of **134.06%**. This means ABT has underperformed the S&P 500 by **-23.78%**. The relative divergence, which measures ABT's performance against the S&P 500 within its historical range, is currently at **17.56**. This means ABT's underperformance is currently in the 17.56th percentile of its historical range.

**Alpha and Beta Analysis:**

The provided table shows the CAGR, MDD, Alpha, and Beta of ABT for different time periods.  

* **CAGR (Compound Annual Growth Rate):** ABT has consistently generated strong CAGR, indicating its ability to grow over time.
* **MDD (Maximum Drawdown):** ABT has experienced relatively low MDDs, indicating its resilience to market downturns.
* **Alpha:** ABT has consistently generated positive alpha, particularly in the period between 2016-2018 and 2017-2019, suggesting it has outperformed the market in those periods.
* **Beta:** ABT's beta has generally been below 1, signifying it is less volatile than the market.

**2. Recent Price Movement:**

ABT's recent price movement shows a slight uptrend:

* **Closing price:** $117.73
* **5-day moving average:** $116.36
* **20-day moving average:** $116.31
* **60-day moving average:** $114.46

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 49.75, indicating the stock is neither overbought nor oversold.
* **PPO (Percentage Price Oscillator):** 0.07, indicating a slight bullish momentum.
* **Delta_Previous_Relative_Divergence:** 3.28 (+), suggesting short-term upward pressure.
* **Expected Return:** 0.0% - Based on the current market conditions and historical performance, ABT is expected to generate a return similar to the S&P 500 over the next 2 years or more.

**4. Recent Earnings and Outlook:**

ABT's recent earnings have been solid:

| Date        | EPS   | Revenue |
|--------------|-------|---------|
| 2024-10-31   | 0.94  | 10.63 B$ |
| 2024-07-31   | 0.74  | 10.38 B$ |
| 2024-05-02   | 0.7   | 9.96 B$ |
| 2023-11-01   | 0.82  | 10.14 B$ |
| 2024-10-31   | 0.82  | 10.14 B$ |

The most recent earnings report (2024-10-31) showed that ABT exceeded analysts' expectations, with EPS of $0.94 compared to an estimated EPS of $0.85. Revenue also exceeded expectations, reaching $10.63B compared to an estimated $10.5B.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter       | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2024-09-30   | $10.63B   | 55.83%       |
| 2024-06-30   | $10.38B   | 55.64%       |
| 2024-03-31   | $9.96B    | 55.21%       |
| 2023-12-31   | $10.24B   | 55.51%       |
| 2023-09-30   | $10.14B   | 54.60%       |

ABT has consistently shown strong revenue and profitability, with a high and stable profit margin. This indicates a strong foundation for the company's future growth.

**Capital and Profitability:**

| Quarter       | Equity    | ROE     |
|--------------|-----------|---------|
| 2024-09-30   | $39.80B  | 4.14%   |
| 2024-06-30   | $39.32B  | 3.31%   |
| 2024-03-31   | $38.81B  | 3.16%   |
| 2023-12-31   | $38.60B  | 4.13%   |
| 2023-09-30   | $37.48B  | 3.83%   |

ABT demonstrates a solid financial position with strong equity and consistent ROE, indicating efficient utilization of shareholder capital.

**6. News and Recent Issues:**

**Recent Earnings News:**

* ABT reported its Q3 2024 earnings on October 31st, 2024, exceeding analysts' expectations on both EPS and revenue. This news generated positive sentiment in the market.

**Recent Market Outlook:**

* According to Finbold, analysts are generally positive about ABT's outlook, with a consensus price target of $120.44.
* ABT's recent performance has been highlighted by its strong earnings and stable business model, indicating a healthy future for the company.

**Analyst Opinions and Performance Highlights:**

* While recent market news has been generally positive, ABT is facing some challenges in certain segments, such as the diagnostics division.
* Analysts continue to track ABT's performance in various sectors and its ability to navigate market fluctuations.

**7. Overall Analysis:**

ABT is a well-established healthcare company with a strong track record of growth and profitability. While it has underperformed the S&P 500 in recent years, it continues to demonstrate healthy fundamentals and a resilient business model. Its recent earnings report suggests positive momentum, and analysts remain generally positive about its future prospects. 

**ABT is a strong candidate for long-term investment for those seeking exposure to the healthcare sector.** Its consistent growth, strong financials, and positive market outlook make it a compelling investment opportunity. However, investors should keep in mind that ABT might experience short-term volatility due to its sensitivity to the market and potential challenges in certain segments.


This analysis is based on the provided data and information. It is important to conduct your own research and consult with a financial professional before making any investment decisions.